CLEVELAND, Sept. 10, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company's MRIdian® and MRIdian Linac MRI-guided radiation therapy systems will be featured at the 2019 Annual Meeting of the American Society for Radiation Oncology (ASTRO), being held September 15-19, 2019 in Chicago. The meeting will feature a number of presentations highlighting the unique capabilities, clinical experience and patient outcomes with ViewRay's MRIdian and MRIdian Linac.

First pioneered by ViewRay in 2012, MRI-Guided ROAR™ (Real-time On-table Adaptive Radiotherapy) represents a new paradigm in cancer treatment. It provides clinicians with the ability to improve targeting precision and accuracy to deliver higher, and potentially more effective, radiation doses.

At this year's ASTRO, more than 20 scientific session presentations/posters will highlight the important role of MRIdian in cancer treatment including the value of its MRI-guidance, targeted dose delivery and automated beam gating. With the added clarity provided by MRIdian real-time imaging, physicians are better equipped to account for any motion caused by respiration or other bodily processes and personalize each treatment.
An ASTRO Industry Expert Theater session on Sunday, September 15 from 2:30 - 3:30 p.m. will feature two talks on the important role of MRIdian in the treatment of prostate and pancreatic cancer. The first by Ben Slotman, M.D., Ph.D., from Amsterdam University Medical Centers is titled "MR-Guided Daily Adaptive SBRT for Prostate Cancer - A Phase 2 Prospective Study," and the second by Michael Chuong, M.D., from Miami Cancer Institute, Baptist Health South Florida is titled "MR-Guided SBRT for Pancreas with On-table Adaptation on MRIdian - MCI Experience."

ViewRay's booth # 3016 will feature presentations from eight MRIdian users covering a wide range of topics and indications including:

MR-Guided Online Adaptive Radiotherapy: Clinical Experience of National Cancer Center Hospital in Japan – Prof. Hiroshi Igaki, M.D., National Cancer Center Japan: Tsukiji Campus
SMART: Status Update on the First Prospective, Multi-Institutional Study on Ablative Pancreas SBRT – Parag Parikh, M.D., Henry Ford Health System
Real-time Targeting: A Necessity for High Precision RT of the Abdomen and Thorax – John Bayouth, Ph.D., University of Wisconsin – Madison
MRI-Guided Liver Radiation: Seeing What You are Missing – Michael Bassetti, M.D., Ph.D., Carbone Cancer Center, University of Wisconsin – Madison
MRI-Guided Prostate RT: See the Cancer, Spare the Toxicity – Himanshu Nagar, M.D., The NewYork-Presbyterian Hospital and Weill Cornell Medicine

MRI Homepage